Millipore Sigma Vibrant Logo

509272 Hydroxychloroquine Sulfate - CAS 747-36-4 - Calbiochem

A cell-permeable compound that increases intralysosomal pH and impairs autophagic degradation process. Suppresses proliferation of human dermal fibroblasts (IC₅₀ = 30 µM).

SDB (Sicherheitsdatenblätter), Analysenzertifikate und Qualitätszertifikate, Dossiers, Broschüren und andere verfügbare Dokumente.

Synonyme: HCQ, Autophagy Inhibitor

View Products on Sigmaaldrich.com
509272
Preis & Verfügbarkeit

Übersicht

Replacement Information

Key Spec Table

CAS #Empirical Formula
747-36-4C₁₈H₂₈ClN₃O₅S

Preis & Verfügbarkeit

Bestellnummer VerfügbarkeitVerpackung St./Pkg. Preis Menge
5.09272.0001
Verfügbarkeit wird abgerufen...
—
Eingeschränkte Verfügbarkeit Eingeschränkte Verfügbarkeit
Lieferbar 
Produkt wurde eingestellt
Begrenzter Lagerbestand
Bestätigung der Verfügbarkeit erforderlich
    Restmenge: Angebot folgt
      Restmenge: Angebot folgt
      Bitte erfragen
      Kontakt zum Kundenservice
      Contact Customer Service

      		 Glasflasche 25 mg
      Preis wird abgerufen...
      Preis nicht abrufbar
      Die Mindestmenge muss ein Vielfaches sein von
      Maximum Quantity is
      Bei Bestätigung Weitere Informationen
      Sie haben () gespart
       
      —
      Bitte erfragen
      		 —
      Description
      OverviewA cell-permeable, orally available quinoline derivative with anti-malarial properties. Increases intralysosomal pH and thereby impairs autophagic degradation process. Reduces metabolic activity and suppresses proliferation of human dermal fibroblasts (IC50 = 30 µM). Shown to inhibit ERK1/2 phosphorylation (Thr202/Try204), but does not affect Akt and mTOR phosphorylation. Shown to directly block the binding of CXCL12 to CXCR4 and inhibit downstream effects in pancreatic cancer cells (EC50 = 9.8 µM). Effectively antagonizes CXCR4-mediated cell proliferation in PANC-1, Hs-766T, and MIAPaCa-2 cells. Suppresses Toll-like receptor 9 (TLR-9)-mediated dendritic cell activation and displays anti-inflammatory properties.

      Please note that the molecular weight for this compound is batch-specific due to variable water content.
      Catalogue Number509272
      Brand Family Calbiochem®
      SynonymsHCQ, Autophagy Inhibitor
      References
      ReferencesKim, J., et al. 2012. PLoS ONE. 7, e31004.
      Ramser, B., et al. 2009. J. Invest. Dermatol. 129, 2419.
      Boya., P., et al. 2005. Mol. Cell. Biol. 22, 1025.
      Oikarinen, A., et al. 2009. J. Invest. Dermatol. 129, 2333.
      Kuznik, A., et al. 2011. J. Immunol. 186, 4794.
      Product Information
      CAS number747-36-4
      FormOff-white powder
      Hill FormulaC₁₈H₂₈ClN₃O₅S
      Chemical formulaC₁₈H₂₈ClN₃O₅S
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥98% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      R PhraseR: 22

      Harmful if swallowed.
      S PhraseS: 36/37/39

      Wear suitable protective clothing, gloves and eye/face protection.
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
      Toxicity Harmful
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Bestellnummer GTIN
      5.09272.0001 04055977241754

      Documentation

      Hydroxychloroquine Sulfate - CAS 747-36-4 - Calbiochem SDB

      Titel

      Sicherheitsdatenblatt (SDB) 

      Hydroxychloroquine Sulfate - CAS 747-36-4 - Calbiochem Analysenzertifikate

      TitelChargennummer
      509272

      Literatur

      Übersicht
      Kim, J., et al. 2012. PLoS ONE. 7, e31004.
      Ramser, B., et al. 2009. J. Invest. Dermatol. 129, 2419.
      Boya., P., et al. 2005. Mol. Cell. Biol. 22, 1025.
      Oikarinen, A., et al. 2009. J. Invest. Dermatol. 129, 2333.
      Kuznik, A., et al. 2011. J. Immunol. 186, 4794.
      Datenblatt

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision14-February-2014 JSW
      SynonymsHCQ, Autophagy Inhibitor
      DescriptionA cell-permeable, orally available quinoline derivative with anti-malarial properties. Increases intralysosomal pH and thereby impairs autophagic degradation process. Reduces metabolic activity and suppresses proliferation of human dermal fibroblasts (IC50 = 30 µM). Shown to inhibit ERK1/2 phosphorylation (Thr202/Try204), but does not affect Akt and mTOR phosphorylation. Shown to directly block the binding of CXCL12 to CXCR4 and inhibit downstream effects in pancreatic cancer cells (EC50 = 9.8 µM). Effectively antagonizes CXCR4-mediated cell proliferation in PANC-1, Hs-766T, and MIAPaCa-2 cells. Suppresses Toll-like receptor 9 (TLR-9)-mediated dendritic cell activation and displays anti-inflammatory properties.
      FormOff-white powder
      Intert gas (Yes/No) Packaged under inert gas
      CAS number747-36-4
      Chemical formulaC₁₈H₂₈ClN₃O₅S
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityH₂O (100 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Harmful
      ReferencesKim, J., et al. 2012. PLoS ONE. 7, e31004.
      Ramser, B., et al. 2009. J. Invest. Dermatol. 129, 2419.
      Boya., P., et al. 2005. Mol. Cell. Biol. 22, 1025.
      Oikarinen, A., et al. 2009. J. Invest. Dermatol. 129, 2333.
      Kuznik, A., et al. 2011. J. Immunol. 186, 4794.